7.47 USD
-0.12 (-1.58%)
7.45 USD
-0.02 (-0.27%)
We assign a fundamental rating of 4 out of 10 to BCRX. BCRX was compared to 529 industry peers in the Biotechnology industry. There are concerns on the financial health of BCRX while its profitability can be described as average. BCRX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
BCRX had negative earnings in the past year.
In the past year BCRX had a positive cash flow from operations.
In the past 5 years BCRX always reported negative net income.
In the past 5 years BCRX always reported negative operating cash flow.
1.2 Ratios
BCRX has a better Return On Assets (-1.97%) than 87.52% of its industry peers.
BCRX's Return On Invested Capital of 23.47% is amongst the best of the industry. BCRX outperforms 98.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.97% | ||
| ROE | N/A | ||
| ROIC | 23.47% |
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BCRX has a Operating Margin of 12.69%. This is amongst the best in the industry. BCRX outperforms 92.25% of its industry peers.
BCRX has a Gross Margin of 97.39%. This is amongst the best in the industry. BCRX outperforms 96.79% of its industry peers.
BCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.69% | ||
| PM (TTM) | N/A | ||
| GM | 97.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
BCRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BCRX has been increased compared to 1 year ago.
Compared to 5 years ago, BCRX has more shares outstanding
BCRX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.99, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.99, BCRX is in line with its industry, outperforming 49.15% of the companies in the same industry.
The Debt to FCF ratio of BCRX is 20.43, which is on the high side as it means it would take BCRX, 20.43 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BCRX (20.43) is better than 89.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 20.43 | ||
| Altman-Z | -1.99 |
ROIC/WACC3.01
WACC7.79%
2.3 Liquidity
BCRX has a Current Ratio of 1.87. This is a normal value and indicates that BCRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.87, BCRX is not doing good in the industry: 78.64% of the companies in the same industry are doing better.
A Quick Ratio of 1.83 indicates that BCRX should not have too much problems paying its short term obligations.
BCRX has a Quick ratio of 1.83. This is in the lower half of the industry: BCRX underperforms 77.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.83%, which is quite impressive.
The Revenue has grown by 45.38% in the past year. This is a very strong growth!
Measured over the past years, BCRX shows a very strong growth in Revenue. The Revenue has been growing by 55.99% on average per year.
EPS 1Y (TTM)94.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%185.71%
Revenue 1Y (TTM)45.38%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%36.14%
3.2 Future
The Earnings Per Share is expected to grow by 43.17% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 19.20% on average over the next years. This is quite good.
EPS Next Y139.02%
EPS Next 2Y63.77%
EPS Next 3Y45.71%
EPS Next 5Y43.17%
Revenue Next Year37.73%
Revenue Next 2Y21.8%
Revenue Next 3Y17.7%
Revenue Next 5Y19.2%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 25.47, the valuation of BCRX can be described as expensive.
93.01% of the companies in the same industry are more expensive than BCRX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.66, BCRX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BCRX is valued cheaply inside the industry as 93.38% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BCRX is valued cheaply inside the industry as 92.44% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.64 | ||
| EV/EBITDA | 24.94 |
4.3 Compensation for Growth
BCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 45.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.77%
EPS Next 3Y45.71%
5. Dividend
5.1 Amount
BCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.47
-0.12 (-1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101%
Inst Owner Change-1.29%
Ins Owners0.51%
Ins Owner Change1.6%
Market Cap1.57B
Revenue(TTM)599.82M
Net Income(TTM)-8.78M
Analysts83.75
Price Target21.05 (181.79%)
Short Float %18.04%
Short Ratio6.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)123.57%
Min EPS beat(2)67.02%
Max EPS beat(2)180.11%
EPS beat(4)3
Avg EPS beat(4)55.88%
Min EPS beat(4)-123.6%
Max EPS beat(4)180.11%
EPS beat(8)5
Avg EPS beat(8)36.47%
EPS beat(12)7
Avg EPS beat(12)16.41%
EPS beat(16)10
Avg EPS beat(16)18.04%
Revenue beat(2)1
Avg Revenue beat(2)1.42%
Min Revenue beat(2)-4.11%
Max Revenue beat(2)6.96%
Revenue beat(4)2
Avg Revenue beat(4)3.6%
Min Revenue beat(4)-4.11%
Max Revenue beat(4)12.47%
Revenue beat(8)6
Avg Revenue beat(8)4.18%
Revenue beat(12)7
Avg Revenue beat(12)2.45%
Revenue beat(16)7
Avg Revenue beat(16)1.1%
PT rev (1m)-2.15%
PT rev (3m)17.01%
EPS NQ rev (1m)-5.68%
EPS NQ rev (3m)26.63%
EPS NY rev (1m)90.44%
EPS NY rev (3m)91.59%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-2.44%
Revenue NY rev (1m)-0.97%
Revenue NY rev (3m)-0.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.47 | ||
| P/S | 2.62 | ||
| P/FCF | 47.64 | ||
| P/OCF | 44.48 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.94 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.29
Fwd EY3.93%
FCF(TTM)0.16
FCFY2.1%
OCF(TTM)0.17
OCFY2.25%
SpS2.85
BVpS-1.84
TBVpS-1.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.97% | ||
| ROE | N/A | ||
| ROCE | 29.7% | ||
| ROIC | 23.47% | ||
| ROICexc | 138.79% | ||
| ROICexgc | 138.79% | ||
| OM | 12.69% | ||
| PM (TTM) | N/A | ||
| GM | 97.39% | ||
| FCFM | 5.5% |
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score5
Asset Turnover1.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 20.43 | ||
| Debt/EBITDA | 8.21 | ||
| Cap/Depr | 179.53% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 2.31 | ||
| Cash Conversion | 45.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | -1.99 |
F-Score5
WACC7.79%
ROIC/WACC3.01
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%185.71%
EPS Next Y139.02%
EPS Next 2Y63.77%
EPS Next 3Y45.71%
EPS Next 5Y43.17%
Revenue 1Y (TTM)45.38%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%36.14%
Revenue Next Year37.73%
Revenue Next 2Y21.8%
Revenue Next 3Y17.7%
Revenue Next 5Y19.2%
EBIT growth 1Y286.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year604.88%
EBIT Next 3Y115.54%
EBIT Next 5YN/A
FCF growth 1Y129.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.12%
OCF growth 3YN/A
OCF growth 5YN/A
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you provide the ChartMill fundamental rating for BIOCRYST PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to BCRX.
What is the valuation status of BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
ChartMill assigns a valuation rating of 5 / 10 to BIOCRYST PHARMACEUTICALS INC (BCRX). This can be considered as Fairly Valued.
Can you provide the profitability details for BIOCRYST PHARMACEUTICALS INC?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a profitability rating of 4 / 10.
Can you provide the financial health for BCRX stock?
The financial health rating of BIOCRYST PHARMACEUTICALS INC (BCRX) is 3 / 10.